Company intelligence / Profile preview

L.R. Research & Development

Israel

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Products and IP contributed to successful EMA/CE-approved therapies for enzymatic debridement of burn wounds, most notably with NexoBrid (by MediWound)

Therapeutic areas: Dermatology
Modalities: BiologicRecombinant proteinEnzyme-based drugs
Industry: Drug Discovery Services

Partnerships

MediWound (Israel/Global)Teva (historical)

Beyond the preview

Go deeper on L.R. Research & Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L.R. Research & Development.

Explore the full profile